Cargando…

Plasma Metabolite Markers of Parkinson’s Disease and Atypical Parkinsonism

Differentiating between Parkinson’s disease (PD) and the atypical Parkinsonian disorders of multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) is difficult clinically due to overlapping symptomatology, especially at early disease stages. Consequently, there is a need to identify...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pathan, Meerakhan, Wu, Junfang, Lakso, Hans-Åke, Forsgren, Lars, Öhman, Anders
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706715/ https://www.ncbi.nlm.nih.gov/pubmed/34940618 http://dx.doi.org/10.3390/metabo11120860

Ejemplares similares

Prediction and early biomarkers of cognitive decline in Parkinson disease and atypical parkinsonism: a population-based study
por: Bäckström, David, et al.
Publicado: (2022)

Plasma Biomarkers Differentiate Parkinson’s Disease From Atypical Parkinsonism Syndromes
por: Lin, Chin-Hsien, et al.
Publicado: (2018)

Retinal Structure Abnormalities in Parkinson’s Disease and Atypical Parkinsonism
por: Ma, Xinxin, et al.
Publicado: (2023)

Orthostatic Hypotension in Patients with Parkinson's Disease and Atypical Parkinsonism
por: Fereshtehnejad, Seyed-Mohammad, et al.
Publicado: (2014)

Inflammation biomarker discovery in Parkinson’s disease and atypical parkinsonisms
por: Santaella, Anna, et al.
Publicado: (2020)

Atypical Ubiquitination and Parkinson’s Disease
por: Buneeva, Olga, et al.
Publicado: (2022)

Early predictors of mortality in parkinsonism and Parkinson disease: A population-based study
por: Bäckström, David, et al.
Publicado: (2018)

Molecular Imaging of the GABAergic System in Parkinson’s Disease and Atypical Parkinsonisms
por: Terkelsen, Miriam H., et al.
Publicado: (2022)

Atypical Gait Cycles in Parkinson’s Disease
por: Ghislieri, Marco, et al.
Publicado: (2021)

Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders
por: Hall, Sara, et al.
Publicado: (2018)

Atypical parkinsonism: an update
por: Stamelou, Maria, et al.
Publicado: (2013)

The diagnostic potential of multimodal neuroimaging measures in Parkinson's disease and atypical parkinsonism
por: Park, Chang‐hyun, et al.
Publicado: (2020)

Promising Metabolite Profiles in the Plasma and CSF of Early Clinical Parkinson's Disease
por: Stoessel, Daniel, et al.
Publicado: (2018)

Longitudinal changes in task-evoked brain responses in Parkinson's disease patients with and without mild cognitive impairment
por: Ekman, Urban, et al.
Publicado: (2014)

Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia
por: Walker, Zuzana, et al.
Publicado: (2018)

Side effects induced by the acute levodopa challenge in Parkinson’s Disease and atypical parkinsonisms
por: Vasta, Rosario, et al.
Publicado: (2017)

Plasma Metabolite Signature Classifies Male LRRK2 Parkinson’s Disease Patients
por: Dong, Chen, et al.
Publicado: (2022)

Phospho-HDAC6 Gathers Into Protein Aggregates in Parkinson’s Disease and Atypical Parkinsonisms
por: Mazzetti, Samanta, et al.
Publicado: (2020)

Serum neuronal exosomes predict and differentiate Parkinson’s disease from atypical parkinsonism
por: Jiang, Cheng, et al.
Publicado: (2020)

TARDBP mutations in a cohort of Italian patients with Parkinson’s disease and atypical parkinsonisms
por: Tiloca, Cinzia, et al.
Publicado: (2022)

Association of Plasma and Electroencephalography Markers With Motor Subtypes of Parkinson’s Disease
por: Yang, Xiaoxia, et al.
Publicado: (2022)

Differences in Striatal Metabolism in [(18)F]FDG PET in Parkinson’s Disease and Atypical Parkinsonism
por: Seiffert, Alexander P., et al.
Publicado: (2022)

Distinct cortical and subcortical predictors of Purdue Pegboard decline in Parkinson’s disease and atypical parkinsonism
por: Wilkes, Bradley J., et al.
Publicado: (2023)

NfL as a biomarker for neurodegeneration and survival in Parkinson disease
por: Bäckström, David, et al.
Publicado: (2020)

Atypical cancer pattern in patients with Parkinson's disease
por: Olsen, J H, et al.
Publicado: (2005)

The role of diffusion magnetic resonance imaging in Parkinson's disease and in the differential diagnosis with atypical parkinsonism
por: de Oliveira, Romulo Varella, et al.
Publicado: (2017)

QEEG Signatures are Associated with Nonmotor Dysfunctions in Parkinson's Disease and Atypical Parkinsonism: An Integrative Analysis
por: Liu, Hailing, et al.
Publicado: (2023)

Strong association between glucocerebrosidase mutations and Parkinson's disease in Sweden
por: Ran, Caroline, et al.
Publicado: (2016)

Parkinson's disease and atypical parkinsonism: the importance of magnetic resonance imaging as a potential biomarker
por: Carrete Jr., Henrique
Publicado: (2017)

Biosignatures for Parkinson’s Disease and Atypical Parkinsonian Disorders Patients
por: Potashkin, Judith A., et al.
Publicado: (2012)

Representation of Parkinson's disease and atypical Parkinson's syndromes in the Czech Republic—A nationwide retrospective study
por: Búřil, Jiří, et al.
Publicado: (2021)

Quantitative susceptibility mapping in atypical Parkinsonisms
por: Mazzucchi, Sonia, et al.
Publicado: (2019)

The Genetic Landscape of Parkinsonism-Related Dystonias and Atypical Parkinsonism-Related Syndromes
por: Diez-Fairen, Monica, et al.
Publicado: (2021)

Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes
por: Saeed, Usman, et al.
Publicado: (2020)

Parkinson's disease or atypical parkinsonism? The importance of acoustic voice analysis in differential diagnosis of speech disorders
por: Kowalska‐Taczanowska, Renata, et al.
Publicado: (2020)

If Not Insulin Resistance so What? – Comparison of Fasting Glycemia in Idiopathic Parkinson’s Disease and Atypical Parkinsonism
por: Chmiela, Tomasz, et al.
Publicado: (2022)

α-Synuclein Reactive Antibodies as Diagnostic Biomarkers in Blood Sera of Parkinson's Disease Patients
por: Yanamandra, Kiran, et al.
Publicado: (2011)

Targeted Multiple Reaction Monitoring Analysis of CSF Identifies UCHL1 and GPNMB as Candidate Biomarkers for ALS
por: Zhu, Shaochun, et al.
Publicado: (2019)

Association of GBA Genotype With Motor and Functional Decline in Patients With Newly Diagnosed Parkinson Disease
por: Maple-Grødem, Jodi, et al.
Publicado: (2021)

Safety of Plasma Infusions in Parkinson's Disease
por: Parker, Jordan E., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k4flqn72tsil40abocjrd4b0oo